Neuroanaesthesia and Coexisting Psychiatric Problems

  • Kiran Jangra
  • Navneh Samagh


Psychiatric illnesses are on the rise throughout the globe mainly due to enhanced awareness and advanced diagnostic modalities [1]. The actual prevalence is also rising due to the changing environmental factors including increasing population, lesser number of jobs, increasing competition at every step, declining moral and ethical values, job stress, altered lifestyles, lesser time available for self-care, etc. [2]. In India, the reported incidence of psychiatric disorders is much lower than the actual incidence of these diseases [3–6]. Unlike the other central nervous system (CNS) disorders, there are no anatomical defects, but there are only functional imbalances between different areas of the brain. In neurosurgical patients, the organic diseases can manifest as psychiatric disorder [7–9]. Most commonly recognised pathway leading to psychiatric disorders is deficiencies of major neurotransmitters of the brain including dopamine, norepinephrine and serotonin [10]. The pharmacological target for treatment of psychiatric illnesses is to increase the concentration of these neurotransmitters at effect site by either inhibiting the metabolism or reducing the reuptake at nerve ending. These psychotropic medications are associated with serious side effects and drug interactions [11].


  1. 1.
    Kaye AD, Hoover JM, Ertner RA, Sutker PB. Behavioral and psychiatric disorders. In: Fliesher LA, editor. Anesthesia and uncommon diseases. 5th ed. Philadelphia, PA: Saunders Elsevier; 2006. p. 469–92.CrossRefGoogle Scholar
  2. 2.
    Chandrashekar CR, Math SB. Psychosomatic disorders in developing countries: current issues and future challenges. Curr Opin Psychiatry. 2006;19:201–6.CrossRefGoogle Scholar
  3. 3.
    Sachdeva JS, Singh S, Sidhu BS, Goyal RK, Singh J. An epidemiological study of psychiatric disorders in rural Faridkot (Punjab). Indian J Psychiatry. 1986;28:317–23.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Premrajan KC, Danabalan M, Chandrasekhar R, Srinivasa DK. Prevalence of psychiatric morbidity in an urban community of Pondicherry. Indian J Psychiatry. 1993;35:99–102.Google Scholar
  5. 5.
    Shaji S, Verghese A, Promodu K, George B, Shibu VP. Prevalence of priority psychiatric disorders in a rural area of Kerala. Indian J Psychiatry. 1995;37:91–6.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Sharma S, Singh MM. Prevalence of mental disorders: an epidemiological study in Goa. Indian J Psychiatry. 2001;43:118–26.Google Scholar
  7. 7.
    Betul O, Ipek M. Brain tumor presenting with psychiatric symptoms. J Neuropsychiatry Clin Neurosci. 2011;23(4):E43–4.CrossRefGoogle Scholar
  8. 8.
    Fleminger S. Long-term psychiatric disorders after traumatic brain injury. Eur J Anaesthesiol Suppl. 2008;42:123–30.CrossRefGoogle Scholar
  9. 9.
    Rödholm M, Starmark JE, Ekholm S, von Esse C. Organic psychiatric disorders after aneurysmal SAH: outcome and associations with age, bleeding severity, and arterial hypertension. Acta Neurol Scand. 2002;106(1):8–18.CrossRefGoogle Scholar
  10. 10.
    Morgan GE, Mikhail MS, Murray MJ. Anesthesia for patients with neurologic and psychiatric diseases. In: Morgan: clinical anaesthesiology. 4th ed. New York: Lange International; 2008. p. 647–61.Google Scholar
  11. 11.
    Dawson J, Karalliedde L. Drug interactions and the clinical anaesthetist. Eur J Anaesthesiol. 1998;15:172–89.CrossRefGoogle Scholar
  12. 12.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.CrossRefGoogle Scholar
  13. 13.
    Bajwa SJ, Jindal R, Kaur J, Singh A. Psychiatric diseases: need for an increased awareness among the anesthesiologists. J Anaesthesiol Clin Pharmacol. 2011;27:440–6.CrossRefGoogle Scholar
  14. 14.
    Attri JP, Bala N, Chatrath V. Psychiatric patient and anaesthesia. Indian J Anaesth. 2012;56(1):8–13.CrossRefGoogle Scholar
  15. 15.
    Montalescot G, Levy Y, Frage D, Brochard L, Fantin B, Arnoux C, et al. Lithium causing a serious sinus-node dysfunction at therapeutic doses. Clin Cardiol. 1984;7:617–20.CrossRefGoogle Scholar
  16. 16.
    Rosenqvist M, Bergfeldt L, Aila H, Mathé AA. Sinus node dysfunction during long-term lithium treatment. Br Heart J. 1993;70:371–5.CrossRefGoogle Scholar
  17. 17.
    Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet. 1995;29:172–91.CrossRefGoogle Scholar
  18. 18.
    Chand PK, Mattoo SK, Sharan P. Quality of life and its correlates in patients with bipolar disorder stabilized on lithium prophylaxis. Psychiatry Clin Neurosci. 2004;58:311–8.CrossRefGoogle Scholar
  19. 19.
    Milenović M, Kalezić N, Simić D, Dimitrijević D, Marković D, Dimitrijević I. Preoperative assessment and management of patient with psychiatric comorbidity. Acta Chir Iugosl. 2011;58(2):143–9.CrossRefGoogle Scholar
  20. 20.
    Slørdal L, Samstad S, Bathen J, Spigset O. A lifethreatening interaction between lithium and celecoxib. Br J Clin Pharmacol. 2003;55(4):413–4.CrossRefGoogle Scholar
  21. 21.
    Handler J. Lithium and antihypertensive medication: a potentially dangerous interaction. J Clin Hypertens (Greenwich). 2009;11:738–42.CrossRefGoogle Scholar
  22. 22.
    Howland RH. Potential adverse effects of discontinuing psychotropic drugs. J Psychosoc Nurs Ment Health Serv. 2010;48:9–12.PubMedGoogle Scholar
  23. 23.
    Girishchandra BG, Khanna S. Phenomenology of obsessive compulsive disorder: a factor analytic approach. Indian J Psychiatry. 2001;43:306–16.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–20.CrossRefGoogle Scholar
  25. 25.
    Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13:100–9.CrossRefGoogle Scholar
  26. 26.
    Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16:615–9.CrossRefGoogle Scholar
  27. 27.
    Hines RL, Marschall KE. Psychiatric disease/substance abuse/drug overdose Stoelting’s: anaesthesia and co-existing disease. 5th ed. Gurgaon: Elsevier.; A division of Reed Elsevier India Private Ltd; 2010. p. 606–29.Google Scholar
  28. 28.
    Ladds B, Thomas P, Mejia C, Hauser D. Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics. Am J Psychiatry. 2009;166:114–5.CrossRefGoogle Scholar
  29. 29.
    Huyse FJ, Touw DJ, van Schijndel RS, de Lange JJ, Slaets JP. Psychotropic drugs and the perioperative period: a proposal for a guideline in elective surgery. Psychosomatics. 2006;47(1):8–22.CrossRefGoogle Scholar
  30. 30.
    Practice advisory for pre-anesthesia evaluation. A report by the American Society of Anesthesiologists. Task force on pre-anesthesia evaluation approved by the house of delegates Oct 17, 2001. Last amended Oct 15, 2003. ASA, Park Ridge, IL.Google Scholar
  31. 31.
    Hemmings HC, Hopkins PM. Foundations of anesthesia: basic sciences for clinical practice. 2nd ed. Philadelphia: Elsevier Health Sciences; 2006. p. 346–7.Google Scholar
  32. 32.
    Sprung J, Distel D, Grass J, et al. Cardiovascular collapse during anesthesia in a patient with preoperatively discontinued chronic MAO inhibitory therapy. J Clin Anesth. 1996;8:662–5.CrossRefGoogle Scholar
  33. 33.
    Chui PT, Chung DCW. Medications to withhold or continue in the perioperative consultation. Curr Anaesth Crit Care. 1998;9:302–6.CrossRefGoogle Scholar
  34. 34.
    McFarlane HJ. Anaesthesia and the new-generation monoamine oxidase inhibitors. Anaesthesia. 1994;49:597–9.CrossRefGoogle Scholar
  35. 35.
    Jefferson JW. A clinician’s guide to monitoring kidney function in lithium-treated patients. J Clin Psychiatry. 2010;71:1153–7.CrossRefGoogle Scholar
  36. 36.
    Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991;48:1082–8.CrossRefGoogle Scholar
  37. 37.
    Meena KP, Vohra AK, Rajput R. Prevalence and pattern of alcohol and substance abuse in urban areas of Rohtak city. Indian J Psychiatry. 2002;44:348–52.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Ghulam R, Rahman I, Naqi S, Gupta SR. An epidemiological study of drug abuse in urban population of Madhya Pradesh. Indian J Psychiatry. 1996;38:160–5.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Jena R, Shukla TR, Hemraj P. Drug abuse in a rural community in Bihar: some psychosocial correlates. Indian J Psychiatry. 1996;38:43–6.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Rudra A, Anjan B, Chatterjee S, Sengupta S, Das T. Anaesthetic implications of substance abuse in adolescent. Indian J Anaesth. 2008;52(2):132–9.Google Scholar
  41. 41.
    Rudra A, Sudipta D. Postoperative pulmonary complications. Indian J Anaesth. 2006;50:89–95.Google Scholar
  42. 42.
    Epie N. The chewing of betal quid and oral submucosal fibrosis andanesthesia. Anesth Analg. 2005;100:1210–3.CrossRefGoogle Scholar
  43. 43.
    Diaz JH, Hill GE. Hypotension with anesthesia in disulfiramtreated patient. Anesthesiology. 1979;51:355–8.CrossRefGoogle Scholar
  44. 44.
    Giuffrida JG, Bizzari DV, Saure AC, et al. Anesthetic management of drug abusers. Anesth Analg. 1970;49:273–82.CrossRefGoogle Scholar
  45. 45.
    Gold MS, Pottash AL, Extein I, Kleber HD. Clonidine in acute opiate withdrawal. N Engl J Med. 1980;302:1421–2.PubMedGoogle Scholar
  46. 46.
    Jage J, Heid F. Substance use disorders and anaesthesia. In: Cashman JN, Grounds RM, editors. Recent advances in anaesthesia and intensive care, vol. 23. Cambridge: Cambridge University Press; 2005. p. 195–216.Google Scholar
  47. 47.
    Wood PR, Soni N. Anaesthesia and substance abuse. Anaesthesia. 1989;44:672–80.CrossRefGoogle Scholar
  48. 48.
    Carlisle EJ, Donnelly SM, Vasuvattakul S, et al. Glue-sniffing and distal renal tubular acidosis: sticking to the facts. J Am Soc Nephrol. 1991;1:1019–27.PubMedGoogle Scholar
  49. 49.
    Murata K, Araki S, Yokoyama K, Yamashita K, Okajima F, Nakaaki K. Changes in autonomic function as determined by ECG R-R interval variability in sandal, shoe and leather workers exposed to n-hexane, xylene and toluene. Neurotoxicology. 1994;15:867–75.PubMedGoogle Scholar
  50. 50.
    Cunnigham SR, Dalzell GW, McGirr P, Kahn MM. Myocardial infarction and primary ventricular fubrillation after glue sniffing. Br Med J. 1987;294:739–40.CrossRefGoogle Scholar
  51. 51.
    Reyes de la Rocha S, Brown MA, Fortenberry JD. Pulmonary function abnormalities in intentional spray paint inhalation. Chest. 1987;92:100–4.CrossRefGoogle Scholar
  52. 52.
    Anderson CE, Loomis GA. Recognition and prevention of inhalant abuse. Am Fam Physician. 2003;68:869–74.PubMedGoogle Scholar
  53. 53.
    Stoelting RK, Dierdorf SF. Psychiatric diseases and substance abuse. In: Stoelting RK, Dierdorf SF, editors. Anesthesia and co-existing disease. 4th ed. New York: Churchill Livingstone; 2002. p. 639–54.Google Scholar
  54. 54.
    Beattie C, Mark L, Umbricht-Schneiter A. Evaluation of the patient with alcoholism and other drug dependencies. In: Rogers MC, Tinker JH, Covino BG, Longnecker DE, editors. Principles and practice of anesthesiology. 1st ed. St. Louis: Mosby; 1993. p. 537–59.Google Scholar
  55. 55.
    Morris G, Magee P. Anaesthesia and past use of LSD. Can J Anaesth. 1995;42:177.CrossRefGoogle Scholar
  56. 56.
    Gold MS, Washton AM, Dackis CA. Cocaine abuse neurochemistry, pharmacology, and treatment. NIDA Res Monogr. 1985;61:130–50.PubMedGoogle Scholar
  57. 57.
    Pitts DK, Marwah J. Autonomic actions of cocaine. Can J Physiol Pharmacol. 1989;67:1168–76.CrossRefGoogle Scholar
  58. 58.
    Fleming JA, Byck R, Barash PG. Pharmacology and therapeutic applications of cocaine. Anesthesiology. 1990;75:518–31.Google Scholar
  59. 59.
    Krane EJ, Davis PJ. Drug-abusing child and adolescent. In: Motoyama EK, Davis PJ, editors. Smith’s anesthesia for infants and children. 7th ed. Philadelphia: Mosby Elsevier; 2006. p. 262–5.Google Scholar
  60. 60.
    Maykut MO. Health consequences of acute and chronic marijuana use. Prog Neuro-Psychopharmacol Biol Psychiatry. 1985;9:209–38.CrossRefGoogle Scholar
  61. 61.
    Stoelting RK, Martz RC, Gartner J, Brown DJ, Forney RB. Effects of delta 9-tetrahydrocannabinol on halothane MAC in dogs. Anesthesiology. 1973;38:521–4.CrossRefGoogle Scholar
  62. 62.
    Michel R, Adams AP. Acute amphetamine abuse. Problems during general anesthesia for neurosurgery. Anaesthesia. 1979;34:1016–9.CrossRefGoogle Scholar
  63. 63.
    Johnston RR, Way WL, Miller RD. Alteration of anesthetic requirement by amphetamine. Anesthesiology. 1972;36:357–63.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Kiran Jangra
    • 1
  • Navneh Samagh
    • 2
  1. 1.Department of Anaesthesia and Intensive CarePGIMERChandigarhIndia
  2. 2.Adesh Institute of Medical Sciences and ResearchBhatindaIndia

Personalised recommendations